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Supplementary table I. Patient characteristics 
 
 UK cohort (n=79) AUS cohort (n=100) 













































































22.7 (95% CI: 
11.4-33.9) 

























































































                      
Gene 
Description 
2029 ENSA X X X X   X     X                   X X 
 




X X X 
          
X 













        
X X 
          
X 








23193 GANAB X     X           X                 X   
 
S glucosidase, alpha; neutral AB 
22927 HABP4 X     X               X   X     X       
 
S hyaluronan binding protein 4 
85014 TMEM14
1 X 
    X                     X           
 
S transmembrane protein 141 
4 
 
11054 OGFR X             X                 X X     
 
S opioid growth factor receptor 
84717 HDGFRP
2 X 
                
X X 





related protein 2 
84263 HSDL2 
X 




    
X 








                        
X 
            
 
S 





                        
X 










OSBPL5 X                                       
 
S oxysterol binding protein-like 5 
84331 FAM195
A X 





195, member A 
90317 ZNF616 X                                       
 
S zinc finger protein 616 
84687 PPP1R9B   
X X 
    
X 
  
X X X 









EVI5L   
X 
  
X X X X 
    
X X 






2801 GOLGA2   X   X   X                     X       
 
S golgin A2 






                            
 
S 
zinc finger and 
BTB domain 
containing 4 




                      
X 











    
X X X 

































family, member 9B 
(with GRAM 
domain) 
23299 BICD2   
X 










4720 NDUFS2   
X 
      
X 
            
X X 
    
X X 











10811 NOXA1   X         X                           
 
S NADPH oxidase activator 1 
5886 RAD23A   X                                     
 
S RAD23 homolog A (S. cerevisiae) 
59 ACTA2   
X 
                                    
 
S 
actin, alpha 2, 
smooth muscle, 
aorta 




          
X 




binding protein 4 
(formin binding 
protein 21) 
29924 EPN1       X   X                             
 
S epsin 1 
57804 POLD4       X       X   X     X         X     
 
S polymerase (DNA-directed), delta 4 
11520
9 
OMA1       
X 
                    
X 







2802 GOLGA3       X                       X         
 
S golgin A3 
37492
0 
C19orf68       
X 




open reading frame 
68 
5433 POLR2D       
X 








FOXP4       X                                 
 
S forkhead box P4 
51754 TMEM8B       X                                 
 
S transmembrane protein 8B 
11093 ADAMT
S13 
      
X 







type 1 motif, 13 
29123 ANKRD1
1 
          X   X         X               
 
S ankyrin repeat domain 11 
22864 R3HDM2           X   X                         
 
S R3H domain containing 2 
2036 EPB41L1           
X 
        
X 





band 4.1-like 1 
84265 POLR3G
L 
          
X 




III (DNA directed) 
polypeptide G 
(32kD)-like 
7461 CLIP2           
X 






23373 CRTC1           
X 






25875 LETMD1               X   X                     
 
S LETM1 domain containing 1 
6 
 
79144 PPDPF                   
X X 









54760 PCSK4                   
X 







9790 BMS1                     
X 






8665 EIF3F                       
X 











                      
X 
                
 
S 
zinc finger with 
KRAB and SCAN 
domains 1 
1632 ECI1                         X   X       X   
 
S enoyl-CoA delta isomerase 1 
166 AES                           X             
 
S amino-terminal enhancer of split 
23265 EXOC7                             X X       X 
 
S exocyst complex component 7 
55624 POMGN
T1 
                              
X X 








3913 LAMB2                                   X     
 
S laminin, beta 2 (laminin S) 
8733 GPAA1                                   
X 






1 homolog (yeast) 
20306
9 





R3H domain and 
coiled-coil 
containing 1 
23351 KHNYN                                       X 
 
S KH and NYN domain containing 
23229 ARHGEF
9 












3, member A 
25870 SUMF2                                         
 
S sulfatase modifying factor 2 
593 BCKDH
A 











ZNF664                                         
 
S zinc finger protein 664 
79090 TRAPPC
6A 

















                                        
 
S uncharacterized LOC642852 






7637 ZNF84                                         
 
S zinc finger protein 84 
11367
5 
SDSL                                         
 
S serine dehydratase-like 




open reading frame 
93 
23408 SIRT5                                         
 
S sirtuin 5 
55420
3 







90321 ZNF766                                         
 
S zinc finger protein 766 






79088 ZNF426                                         
 





                                        
 





Supplementary Table 3 Connectivity map analysis 
Drug Replicate p value Z score 
    
BRD-K71103788__duloxetine hcl 48 1.85E-10 -6.2659907 
BRD-K75641298__METOCLOPRAMIDE 
HYDROCHLORIDE 
29 2.77E-09 -5.8298123 
BRD-K36862742__hydro-flumethiazide 141 3.04E-08 -5.4165957 
BRD-K99964838__S1014 66 6.16E-08 -5.2888016 
BRD-A45889380__QUINACRINE 
HYDROCHLORIDE 
206 8.03E-08 -5.240004 
BRD-K91699951__benzonatate 234 1.39E-07 -5.1383754 
BRD-K71879491__ATRA 205 2.17E-07 -5.0531872 
BRD-A51820102__econazole 36 2.22E-07 -5.0489293 
BRD-K37270826__mifepristone 125 2.62E-07 -5.0175175 
BRD-K70487031__cis-(Z)-
FLUPENTHIXOL 
27 3.03E-07 -4.9893544 
BRD-K63675182__triflupromazine 179 5.12E-07 -4.8868451 
BRD-K89375097__pirenzepine 36 6.96E-07 -4.826062 
BRD-K19706299__MRE-269 99 7.54E-07 -4.8102311 
BRD-K32164935__TOLAZAMIDE 353 1.17E-06 -4.7219067 
BRD-K28936863__ketotifen 85 1.18E-06 -4.7204909 
BRD-A23723433__paclitaxel 48 1.22E-06 -4.7138292 
BRD-K39621635__artemether 34 1.25E-06 -4.7081455 
BRD-K81418486__SAHA__trt_poscon 12 1.36E-06 -4.6910799 
BRD-K92093830__doxorubicin 159 1.58E-06 -4.6599437 
BRD-A49160188__donepezil 73 1.74E-06 -4.6404777 
BRD-K70487031__flupentixol 37 2.14E-06 -4.5971052 
BRD-K10916986__S1527 67 2.20E-06 -4.5915996 
BRD-K92778217__mefenamic-acid 160 2.39E-06 -4.5741376 
BRD-K13514097__S1120 58 3.79E-06 -4.4764562 
BRD-K45995181__Auranofin 3 3.84E-06 -4.474083 
BRD-K66175015__S1011 59 4.68E-06 -4.4316279 
BRD-K53737926__amitryptiline 137 4.95E-06 -4.4194573 
BRD-K52075040__cerulenin 210 5.16E-06 -4.4103748 
BRD-K20075662__betazole 143 5.27E-06 -4.4059091 
BRD-K33106058__cytarabine 48 5.52E-06 -4.395691 
BRD-K91290917__Amodiaquin 
dihydrochloride dihydrate 
57 5.65E-06 -4.3905396 
BRD-K81418486__vorinostat 1303 6.50E-06 -4.360225 
BRD-K93754473__tamoxifen 843 6.59E-06 -4.3571007 
BRD-K25433859__maprotiline 37 9.22E-06 -4.2829289 
BRD-K39339537__epirizole 217 1.16E-05 -4.2316941 
BRD-A45889380__Quinacrine 
dihydrochloride dihydrate 
10 1.58E-05 -4.1619013 
BRD-K81528515__HY-10159 66 1.60E-05 -4.1585908 
9 
 
BRD-K17016787__estriol 355 1.78E-05 -4.1344654 
BRD-K21680192__mitoxantrone 334 1.91E-05 -4.1181513 
BRD-K41260949__Sodium Valproate 45 2.33E-05 -4.0721889 
BRD-K39987650__BISACODYL 93 2.54E-05 -4.0520213 
BRD-K89997465__CHLORPROMAZINE 86 2.68E-05 -4.0390003 
BRD-
K81418486__VORINOSTAT__trt_poscon 
2575 3.07E-05 -4.0072094 
BRD-K63750851__mycophenolic-acid 31 3.78E-05 -3.9582377 
BRD-K47869605__podofilox 72 3.85E-05 -3.9538222 
BRD-K61250553__Loperamide.HCl 23 3.91E-05 -3.9501318 
BRD-K20168442__vecuronium 49 4.36E-05 -3.9234926 
BRD-K61250553__imodium 45 4.38E-05 -3.9224636 
BRD-A29734509__norpace 44 5.30E-05 -3.8764725 
BRD-K28143534__Cyproheptadine 
hydrochloride 
10 1.07E-04 -3.7019795 
BRD-K86434416__deprenalin 88 1.31E-04 -3.6498136 
 
SUPPLEMENTARY METHODS 
Clonogenic assays  
5000 cells per well were seeded in 12 well plates and left untreated or treated with 
EPZ015666 (1 µM, 5 µM, 10 µM). The PRMT5 inhibitor EPZ015666 was obtained from 
Selleckchem (Ely, UK). 
Five days after treatment, cells were fixed on ice in methanol for 20 minutes. Cells 
were then stained with crystal violet (Sigma, Gillingham, UK) for 10 minutes. Colonies 
were dissolved in 30% acetic acid to allow quantification. Each treatment condition 
was measured in triplicate. 
 
siRNA transfections  
The non-silencing control (NT) and siRIOK, were obtained from and Qiagen 
(Manchester, UK). siRNA transfections (20 nM) were performed using the RNAiMAX 




Flow Cytometry  
Samples were analysed on a BD FACS Calibur flow cytometer machine, using Cell 
Quest Pro software (Becton Dickinson, Oxford, UK). Cells were fixed after 16, 32, 72 
and 120 hours of treatment with quinacrine, EPZ015666 or after silencing of PRMT5 
and stained with propidium iodide (Sigma).  
 
Gene expression  
NCI-H2591 and NCI-H2052 cells were transfected with non-silencing control (NT), 
siPRMT5 Qiagen and siPRMT5 Dharmacon. RNA was extracted 120h after 
transfection with the RNeasy Mini Kit (Qiagen, Manchester, UK) and 100 ng of RNA 
were hybridised on the SurePrint G3 Human Gene Expression v3 8x60k array (Agilent, 
Cheadle, UK).  
 
Gene expression dataset was analysed using Limma in R/Bioconductor software 
package.  Comparisons were performed siQ vs siNT, siD vs siNT.  Gene lists were 
then filtered by fold change ≥2, unadjusted p value ≤ 0.05. Webgestalt 
(http://www.webgestalt.org/) was used to perform Gene Ontology, KEGG pathway, 
Pathway Common, Wiki Pathway. GSEA Molecular Signatures Database 
(http://software.broadinstitute.org/gsea/msigdb/index.jsp) was used to investigate 85 





SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure 1. A) Cells were transfected with siNT or siRIOK1 20 nM. Cell 
proliferation was measured by clonogenic assay. Data were normalized to siNT 
controls (NCI-H2591: p= n.s.; NCI-H2052: p=0.0001; NCI-H2452: p=n.s; MPP89: p= 
n.s.). The levels of PRMT5 expression and H4 arginine 3 symmetrical di-methylation 
(H4R3me2S) were measured by western blot 72 hours after transfection. These gels 
have been cropped and the full length gels are presented in Supplementary Figure 3 
M-O. B) Flow cytometry plot showing cells transfected with siNT or siPRMT5 for 120 
hours. C) Cells were left untreated or treated with EPZ015666 1µM, 5 µM and 10µM. 
Cell proliferation was measured by clonogenic assay 5-7 days after treatment. Data 
were normalized to untreated controls (NCI-H2591: 1 µM p=0.0176; 5 µM p=0.0001; 
10 µM p=0.0001; NCI-H2052: 1 µM p=n.s.; 5 µM p= n.s. 10 µM p=0.0033; MPP89: 1 
µM p=n.s.; 5 µM p= n.s. 10 µM p= n.s.). D) Flow cytometry plot showing cells left 
untreated or treated with EPZ015666 5 µM and 10µM for 72 hours. 
 
Supplementary Figure 2. Flow cytometry plot showing cells left untreated or treated 
with quinacrine 1 µM for 120 hours. B) Flow cytometry plot showing cells transfected 
with siNT, sic-JUN 20 nM, for 120 hours.  
Supplementary Figure 3. Uncropped images of full length gels used throughout the 
manuscript. A-C: Full length gels of cropped gels in Figure 1C (A: NCI-H2591; B: NCI-
H2052; C: MPP89); D-F: Full length gels of cropped gels in Figure 1D (D: NCI-H2591; 
E: NCI-2052; F: MPP89); G-I: Full length gels of cropped gels in Figure 3C (G: NCI-
H2591; H: NCI-H2052; I: MPP89); J-K: Full length gels of cropped gels in Figure 4B 
(J: NCI-H2591; K: NCI-H2052); L: Full length gel of cropped gel in Figure 4E; M-O: 
12 
 
Full length gels of cropped gels in Supplementary Figure 1A (M: NCI-H2591; N: NCI-
H2052; O: MPP89). 



























Supplementary Figure 3. 
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